-
Innovation Ranking
Innovation Ranking – XOMA Corp
XOMA Corp (Xoma), formerly Xoma Ltd, is a biopharmaceutical company. It develops antibody-based therapeutics. Its lead product, Gevokizumab is a monoclonal antibody used for the treatment of a wide variety of inflammatory diseases and other diseases. Its other pipeline products include RZ358, TAK-079, AZD2936 and PTH1R. XOMA X358 is a human negative allosteric modulating insulin receptor antibody. Xoma has a developed proprietary antibody platform, optimization and development technologies, comprising ADAPT, ModulX and OptimX. It operates through its subsidiaries in Bermuda,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gevokizumab in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gevokizumab in Metastatic Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gevokizumab in Metastatic Colorectal Cancer Drug Details: Gevokizumab (XOMA-052) is developing...
-
Product Insights
NewNet Present Value Model: XOMA Corp’s Iscalimab
Empower your strategies with our Net Present Value Model: XOMA Corp's Iscalimab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: XOMA Corp’s RZ-358
Empower your strategies with our Net Present Value Model: XOMA Corp's RZ-358 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewHumoral Hypercalcemia of Malignancy – Drugs In Development, 2024
Empower your strategies with our Humoral Hypercalcemia of Malignancy – Drugs In Development, 2024 report and make more profitable business decisions. Humoral hypercalcemia of malignancy (HHM) is caused by too much parathyroid hormone-related peptide (PTHrP) from malignant tumors. Primary hyperparathyroidism, PTH production by malignant cells, local osteolytic hypercalcemia, ectopic hyperparathyroidism, and vitamin D-secreting lymphomas can cause HHM. Symptoms include anxiety, depression, cognitive dysfunction, lethargy, weakness, fatigue, hyporeflexia, confusion, stupor, and in the most severe cases, coma. PTH and vitamin D levels,...
-
Product Insights
NewHyperparathyroidism – Drugs In Development, 2024
Empower your strategies with our Hyperparathyroidism – Drugs In Development, 2024 report and make more profitable business decisions. Hyperparathyroidism is an increase in parathyroid hormone (PTH) levels in the blood. In hyperparathyroidism, one or more of parathyroid glands becomes overactive and makes excess PTH. This could be due to a tumor, gland enlargement, or other structural problems of the parathyroid glands.Symptoms of hyperparathyroidism are caused by inappropriately normal or elevated blood calcium leaving the bones and flowing into the blood stream...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RZ-358 in Hyperinsulinemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RZ-358 in Hyperinsulinemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.RZ-358 in HyperinsulinemiaDrug Details: RZ-358 (XOMA-358) is under development for the treatment of hyperinsulinemic...
-
Product Insights
Uveitis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Uveitis Clinical Trials Market Report Overview The uveitis clinical trial market research report provides an overview of the uveitis clinical trials scenario. The report provides top-line data relating to the clinical trials on uveitis. It also includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type. Key Regions North America,...